The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial
| Authors | |
|---|---|
| Year of publication | 2005 |
| Type | Article in Periodical |
| Magazine / Source | Parkinsonism and Related Disorders |
| MU Faculty or unit | |
| Citation | |
| Field | Neurology, neurosurgery, neurosciences |
| Keywords | Parkinson disease; pergolid; sexual dysfunction |
| Description | Fourteen male patients suffering from Parkinson's disease, each of whom had been treated with L-DOPA, and in whom additional treatment with oral dopamine agonist (DA) was needed, were followed for a period of one year. Pergolide mesylate was given to each patient, and titrated to a total daily dose of 3 mg. All of the patients were taking L-DOPA. The assessments consisted of neurological examination, unified Parkinson's disease rating scale (UPDRS) III and IV subscales scoring, mini mental state examination (MMSE) scoring, the neuropsychological examination, biochemical and hematological examinations and a sexological examination during which the patients filled-in the international index of erectile function (IIEF) questionnaire. Pergolide mesylate significantly improved all sexual functions in younger male Parkinsonian patients who were still interested in sexual activities. |
| Related projects: |